Everlume Bio的动态

Publication Spotlight: Evolving Gene Delivery Through Collaborative Efforts! Read the article: https://bit.ly/4bcqrKq A research team from the University of Minnesota, led by Joseph Skeate, of the Branden Moriarity and Beau Webber labs, teamed up Neil Otto, Ph.D. and our Cell and Gene Therapy R&D team. Together they generated a hyperactive transposase (TcBuster?) for non-viral gene delivery through directed evolution. Their engineering pipeline for T and NK cell therapies, leveraging TcBuster, demonstrated robust functional delivery of large, multicistronic cargo in vitro and in vivo. With this breakthrough, costs and timelines associated with cell engineering are significantly reduced, accelerating the development and accessibility of future cell therapies. Now published in Molecular Therapy, you can see the data for yourself! #celltherapy

Groundbreaking interventions, like cell and?gene therapies, personalized medicine, and?mRNA, require a new approach to clinical?trials. That’s why we created Next-Gen Clinical?Development for Life Sciences – a new offer?from Capgemini that helps companies?streamline the clinical development process?and bring new treatments to market faster.? ? Check out our latest video and accompanying?point of view to learn more about how your?organization can take clinical development to?the next level???https://bit.ly/3SKtKT1 #lifesciences ?#clinicaldevelopment ?#Innovation #nextgenclinicaldevelopment?

Join this amazing discussion!

?? Innovation in Cell and Gene Therapy: Leveraging Recent FDA and EMA Approvals for CRISPR-Based Therapies ?? Recent FDA and EMA approvals for CRISPR-based therapies have ignited a wave of innovation in cell and gene therapy development. Navigating these advancements requires a deep understanding of the diverse manufacturing approaches and their unique requirements. ?? Read our new whitepaper, Next-Generation CRISPR Approaches, to learn more. Aldevron "CMN Advertising" https://lnkd.in/d-SVj4mp

microRNAs (miRNAs) are a class of small, non-coding RNA molecules, typically comprising about 18–25 nucleotides in length. These molecules play a pivotal role in post-transcriptional regulation of gene expression. miRNAs exert their function primarily by binding to the 3′ untranslated region (3′ UTR) of target messenger RNA (mRNA) molecules, leading to mRNA degradation or translational repression. As a result, miRNAs are instrumental in regulating various cellular processes, including differentiation, proliferation, apoptosis, and metabolism. Due to their extensive regulatory functions, miRNAs are implicated in multiple physiological and pathological processes, including those associated with obesity and metabolic disorders. DOI: https://rdcu.be/dNO0G https://hri.drmhany.com/ #HRI #bariatric #bariatricsurgery #weightloss #weightlossjourney #gastricsleeve #weightlosssurgery #gastricbypass #bariatric #bariatriclife

Transcription factors are proteins that control gene expression by binding to specific DNA sequences. They regulate the rate at which genes are transcribed into mRNA, either activating or repressing transcription. These proteins are crucial for processes like development and response to environmental signals. Dysregulation of transcription factor activity can lead to diseases like cancer. Understanding their function is key to developing targeted therapies. #science

? Landmark Bio’s Eli Kraus, Yun Chen,Ph.D., Manish Tandon and Gregg Nyberg, demonstrate application of a rapid analytical method in cutting-edge Extracellular Vesicle (EV)-based therapy biomanufacturing. Based on widely available conventional Flow Cytometer configurations, the method development was presented at the ECI Advancing Manufacture of Cell and Gene Therapies Conference in Coronado, CA. Read about the accuracy, precision, and reliable EV quantitation by Flow Cytometry, its benefit, criticality, and limitation in directly supporting clinical EV biomanufacturing platforms. #ExtracellularVesicles #FlowCytometry ?

It was exciting to talk about future of Cell and Gene Therapy and application of AI/ML in ASA Industry-Regulatory Statistics Workshop. Thanks for organizing this session Patricia! #BMS_Employee #AI #CGT.

?? The countdown is on until ACT’s 2024 Meeting Symposium! We’re excited to share that Akkeri, Inc.’s very own Ewa Budzynski will be chairing a highly anticipated session on AAV Gene Therapy. This session will cover preclinical strategies and safety considerations for targeting critical organs, including the ear, eye, and spinal cord. It’s going to be a valuable discussion for anyone interested in the cutting-edge advancements of gene therapy. Akkeri’s team will be there and eager to connect, share insights, and discuss the latest trends and innovations in the industry! #ACT2024 #GeneTherapy #AAVGeneTherapy #PreclinicalResearch #Akkeri #BiotechInnovation #Healthcare #MedicalResearch

If you are interested in learning more about the latest biostatistical thinking in #cellandgenetherapies, check out this upcoming event! #iconplc